Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: May 2, 2025
Event: Entry into a Material Definitive Agreement (Warrant Inducement Agreement) and subsequent closing of transactions on May 5, 2025.
Key Financial Metrics
- Gross Proceeds: Approximately $2.75 million received from the exercise of existing warrants.
- Shares Issued: 3,718,440 shares of Common Stock issued upon exercise of Series B and Series C Warrants.
- Exercise Price: Reduced to $0.74 per share for the existing warrants.
- Transaction Costs:
- Financial advisory fee to A.G.P./Alliance Global Partners: $160,561.65.
- Legal fees: $25,000.
- Tail fee to H.C. Wainwright & Co., LLC: 8% of gross proceeds (approx. $220,000) plus issuance of 223,106 Prior Placement Agent Warrants.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and New Securities
In consideration for the immediate exercise of existing warrants, the Company issued new unregistered warrants ("New Warrants") to the Holder:
- Series B-1 Warrants: To purchase up to 2,482,270 shares; 5-year term from Stockholder Approval Date.
- Series C-1 Warrants: To purchase up to 4,025,000 shares; 18-month term from Stockholder Approval Date.
- Total New Warrant Shares: 6,507,270 shares.
- Exercise Price of New Warrants: $0.74 per share (subject to adjustment).
- Lock-up: The Company agreed not to issue common stock or file registration statements for 30 days following the closing, subject to exceptions.
Guidance, Outlook, and Risks
- Registration Obligations: The Company must file a resale registration statement for the New Warrant Shares within 45 days of closing and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if a full review is required).
- Cashless Exercise: If a registration statement is not effective 6 months after issuance, the New Warrants may be exercised via cashless exercise.
- Ownership Caps: Exercise is limited if it would cause the holder to beneficially own more than 4.99% or 9.99% of outstanding shares.
- Stockholder Approval: The New Warrants are exercisable only after the Company receives stockholder approval of their exercisability.
- Unregistered Status: The New Warrants and Prior Placement Agent Warrants are unregistered and cannot be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% tail fee and other transaction costs.
- Confirm the timeline for the filing and effectiveness of the Resale Registration Statement for the New Warrants.
- Monitor the schedule for the required stockholder vote to approve the exercisability of the New Warrants.
- Review the full text of the Warrant Inducement Agreement (Exhibit 10.1) for specific adjustment mechanisms and fundamental transaction provisions.
- Assess the dilution impact of the 6,507,270 new warrant shares relative to the current share count.